TopoGEN is partnering with a prominent analytical chemist based in South Africa on the development of innovative anti-topo I and II targeting drugs based on synthetic structures containing gold. Evidence demonstrates the combination of poisoning and catalytic inhibition of the DNA topoisomerase pathways. Initial screens performed by NCI demonstrated efficacy in cancer and subsequent confirmation by TopoGEN is showing topoisomerase targeting. Further studies are pending SBIR phase I review and the acquisition of patents filed in the U.S. and abroad.
The Banobagi Korean Surgery speaks about how can it affect the body, and which surgery is the right one for the stage the patient encounters.
The aim of this study was to check the anticancer activity and the detailed mechanism of the most active diisoquinoline derivatives in human gastric cancer cells (AGS). After preliminary study, the most cytotoxic agents (1 and 2) were selected for further investigations. Their anticancer potential was compared with etoposide, which is a commonly known chemotherapeutic agent in gastric cancer treatment. The effect of the tested compounds (1, 2, etoposide) on viability, DNA biosynthesis and cell cycle in AGS cells was investigated. Electrophoresis was performed to prove that the compounds are topoisomerase II inhibitors. Annexin V binding assay and dual acridine orange/ethidium bromide staining were used to confirm apoptosis induction. Bioimaging was applied as a tool to explain in detail the molecular mechanism of the compounds tested. The expressions of pivotal proteins involved in apoptosis and cell signaling, such as initiator and effector caspases: −9 and 3, p53, AKT, ERK1/2 were analyzed.
Check back for further details.